{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00018699", "CSN": null, "TRF": "ORD_1289646_01", "MRN": "10033199", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1022478", "clinicalId": "1023858", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1289646_01", "SampleName": "US1240879.01", "Version": "0", "Sample": {"FM_Id": "ORD_1289646_01", "SampleId": "US1240879.01", "BlockId": "nan", "TRFNumber": "ORD_1289646_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_01_28", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "Elevated Tumor Fraction Not Detected", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98311", "MRN": "10033199", "FullName": "\u55bb\u71d5\u73b2", "FirstName": "Yen_Ling", "LastName": "Yu", "SubmittedDiagnosis": "Adenocarcinoma, Gallbladder (From S111-70118)", "Gender": "Female", "DOB": "1950_12_27", "OrderingMD": "\u76e7\u4fca\u826f", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_01_24", "ReceivedDate": "2022-02-10 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Gallbladder Cancer"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "14", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "2"}, "VariantProperties": {"VariantProperty": [{"geneName": "ALK", "isVUS": "true", "variantName": "V163L,V867I"}, {"geneName": "DDR1", "isVUS": "true", "variantName": "V208M"}, {"geneName": "MLH1", "isVUS": "true", "variantName": "R217C"}, {"geneName": "MLL2", "isVUS": "true", "variantName": "Q4254R"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "Q1134R"}, {"geneName": "NOTCH2", "isVUS": "true", "variantName": "S220R"}, {"geneName": "NSD3 (WHSC1L1)", "isVUS": "true", "variantName": "D679G"}, {"geneName": "XRCC2", "isVUS": "true", "variantName": "V39M"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "PIK3CA", "Include": "true", "Alterations": {"Alteration": {"Name": "E545K", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E545K"}}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007,Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477). PIK3CA mutations have been reported in 0_6% of intrahepatic cholangiocarcinoma cases and in 4_13% of gallbladder carcinoma cases (Riener et al., 2008; 18181165, Deshpande et al., 2011; 21303542, Borger et al., 2012; 22180306, Jang et al., 2013; 24186137, Voss et al., 2013; 23391413, Ross et al., 2014; 24563076), although one study of Chinese patients with cholangiocarcinoma reported PIK3CA mutations in 32% of tumors (Xu et al., 2011; 21051183). PIK3CA mutations appear to be more common in intraductal papillary mucinous neoplasm/carcinoma while rarely observed in the more common and aggressive ductal adenocarcinoma of the pancreas (Sch\u00f6nleben et al., 2008; 18343945, Yamaguchi et al., 2011; 21945955, Sch\u00f6nleben et al., 2006; 16778113, Xiao et al., 2011; 21547907, Kuboki et al., 2010; 20495538, Sch\u00f6nleben et al., 2009; 19440799). Published data investigating the prognostic implications of PIK3CA alterations in biliary tract carcinoma are limited (PubMed, Jul 2021). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452). In the Phase 2 MATCH trial for patients with PIK3CA_mutated solid tumors, 28% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). A separate Phase 1b study of taselisib in combination with the CDK4/6 inhibitor palbociclib for patients with PIK3CA_mutated solid tumors reported an ORR of 0% (n=12) and a DCR of 17% (2/12) (Pascual et al., 2021; 32958578). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib demonstrated an ORR of 6.0% (8/134) and a DCR of 58% (78/134) in a study for patients with PIK3CA_mutated solid tumors (Juric et al., 2018; 2941002). However, the PI3K inhibitor copanlisib exhibited limited efficacy in PIK3CA_mutated tumors (Santin et al., 2020; 31934607, Patnaik et al., 2016; 27672108).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Temsirolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of temsirolimus for the treatment of biliary tract cancers are limited (PubMed, Jan 2022). A Phase 1 trial of bevacizumab and temsirolimus plus liposomal doxorubicin in patients with advanced solid tumors showed that the combination was well tolerated and resulted in six_month SD in 21% of patients, with a 21% rate of partial or complete remission (Moroney et al., 2012; 22927482). In a Phase 2 clinical trial in non_small cell lung cancer (NSCLC), temsirolimus showed clinical benefit, but further studies are warranted (Reungwetwattana et al., 2012; 22722792). A Phase 2 study of temsirolimus in patients with KRAS_mutant colorectal cancer reported limited efficacy; however, all patients who exhibited tumor reduction were found to have low levels of mutated KRAS in plasma samples (Spindler et al., 2013; 23514584). A Phase 2 clinical trial in patients with pancreatic cancer reported that temsirolimus monotherapy had limited efficacy, and may have contributed to disease progression (Javle et al., 2010; 20630061). A study examining the efficacy of temsirolimus_involving regimens in 24 patients with mesenchymal/metaplastic breast cancer (MpBCs) reported 2 CRs, 4 PRs, 2 instances of SD longer than 6 months, and 4 instances of SD shorter than 6 months (Moulder et al., 2015; 25878190). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Everolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Of 2 patients with PIK3CA_mutated advanced biliary tract cancer included in the Phase 2 RADiChol study, 1 experienced prolonged PFS of 16.7 months with everolimus (Lau et al., 2018; 29527009). Case studies have reported additional patients with PIK3CA_mutated gallbladder carcinoma or cholangiocarcinoma who benefited from everolimus treatment (Feng et al., 2020; 32323774, Bian et al., 2017; 28694672). A Phase 2 study of everolimus in patients with advanced biliary tract cancer showed 2.6% (1/38) PR and 42.1% (16/38) SD, and a median PFS of 3.2 months (Buzzoni et al., 2014; 24827133). Another Phase 2 study of everolimus in patients with biliary tract cancer reported 7.4% (2/27) PR, 48.1% (13/27) SD, and a median PFS of 6 months (Yeung et al., 2014; ASCO Abstract 4101). An observational study of everolimus in biliary tract cancer reported a disease control rate of 50%, but a high incidence (64%) of severe toxicities in patients with biliary tract cancer (Verzoni et al., 2014; 25145431). A Phase 1 trial of everolimus combined with sorafenib reported SD >10 weeks in 62% of cholangiocarcinoma patients (You et al., 2016; ASCO Abstract 2532). A Phase 1 trial evaluating everolimus in combination with gemcitabine and/or cisplatin for the treatment of patients with solid tumors reported 0% PR, 60% SD, and 40% PD in an expansion cohort of 10 patients with cholangiocarcinoma or gallbladder carcinoma (Costello et al., 2014; 24740268). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT03768375", "Include": "true"}, {"nctId": "NCT02688881", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT04632992", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2021). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study (Nakamura et al., 2015; 26258846), TMB_high (\u226510 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB_high tumors experienced numerically longer OS compared with patients with TMB_low tumors (11.5 vs. 8.4 months, adjusted HR=0.65) (Shao et al., 2020; 33119110). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "DNMT3A", "Include": "true", "Alterations": {"Alteration": {"Name": "E240fs*72", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E240fs*72"}}, "Interpretation": "The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Ch\u00e9din, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallb\u00f6hmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Alterations such as seen here may disrupt DNMT3A function or expression (Chen et al., 2005; 15861382, Guo et al., 2015; 25383530, Sandoval et al., 2019; 30705090, Zhang et al., 2018; 29414941). DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_H has been variously reported in 0_42% of gallbladder carcinomas (Moy et al., 2015; 25680569, Mishra et al., 2009; 19866438, Nagahashi et al., 2008; 18176964, Saetta et al., 2006; 15963980, Roa et al., 2005; 15692793, Sessa et al., 2003; 12766614, Rashid et al., 2002; 12374683). MSI_H is infrequent in cholangiocarcinoma, reported in 1% of samples (Javle et al., 2019; ASCO Abstract 4087). A non_zero level of MSI has been reported in 18_49% of cholangiocarcinoma cases (Momoi et al., 2001; 11580146, Limpaiboon et al., 2002; 12175538, Liu et al., 2002; 12402306, Liengswangwong et al., 2003; 14506736), although the studies did not specify what fraction of cases were MSI_H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast (Liu et al., 2002; 12402306). No significant difference in median overall survival or prognosis was found in MSI_H gallbladder carcinomas when compared to MSS cases (Moy et al., 2015; 25680569, Roa et al., 2005; 15692793, Rashid et al., 2002; 12374683). One study reported that MSI is associated with poor prognosis in liver fluke_related cholangiocarcinoma (Limpaiboon et al., 2002; 12175538). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction Not Detected"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction values have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. However, if elevated tumor fraction is not detected, it does not exclude the presence of disease burden or compromise the confidence of reported alterations. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha", "Locations": "Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Tainan (Taiwan), Seoul (Korea, Republic of), Beijing (China), Woolloongabba (Australia), Darlinghurst (Australia), Randwick (Australia), Melbourne (Australia), Haifa (Israel)", "NCTID": "NCT04589845", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma", "StudyPhase": "PHASE 2", "Target": "EGFR, mTOR, ERBB2", "Locations": "Shanghai (China)", "NCTID": "NCT03768375", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors", "StudyPhase": "PHASE 4", "Target": "mTOR", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT02688881", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Alaska, Washington", "NCTID": "NCT03994796", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, PD_L1, ERBB2, PI3K_alpha, RET, AKTs", "Locations": "Alaska, Washington, Oregon, California, Montana", "NCTID": "NCT04632992", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "15950905", "FullCitation": "Samuels Y, et al. Cancer Cell (2005) pmid: 15950905", "Include": "true"}, {"number": "1", "ReferenceId": "19629070", "FullCitation": "Nat. Rev. Cancer (2009) pmid: 19629070", "Include": "true"}, {"number": "2", "ReferenceId": "15647370", "FullCitation": "Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370", "Include": "true"}, {"number": "3", "ReferenceId": "15930273", "FullCitation": "Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273", "Include": "true"}, {"number": "4", "ReferenceId": "17376864", "FullCitation": "Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864", "Include": "true"}, {"number": "5", "ReferenceId": "18317450", "FullCitation": "Horn S, et al. Oncogene (2008) pmid: 18317450", "Include": "true"}, {"number": "6", "ReferenceId": "21266528", "FullCitation": "Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528", "Include": "true"}, {"number": "7", "ReferenceId": "22120714", "FullCitation": "Hon WC, et al. Oncogene (2012) pmid: 22120714", "Include": "true"}, {"number": "8", "ReferenceId": "22949682", "FullCitation": "Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682", "Include": "true"}, {"number": "9", "ReferenceId": "19915146", "FullCitation": "Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146", "Include": "true"}, {"number": "10", "ReferenceId": "2103068", "FullCitation": "Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068", "Include": "true"}, {"number": "11", "ReferenceId": "20530683", "FullCitation": "Dan S, et al. Cancer Res. (2010) pmid: 20530683", "Include": "true"}, {"number": "12", "ReferenceId": "18829572", "FullCitation": "Oda K, et al. Cancer Res. (2008) pmid: 18829572", "Include": "true"}, {"number": "13", "ReferenceId": "18794883", "FullCitation": "Zhao L, et al. Oncogene (2008) pmid: 18794883", "Include": "true"}, {"number": "14", "ReferenceId": "23619167", "FullCitation": "Lui VW, et al. Cancer Discov (2013) pmid: 23619167", "Include": "true"}, {"number": "15", "ReferenceId": "22430209", "FullCitation": "Ross RL, et al. Oncogene (2013) pmid: 22430209", "Include": "true"}, {"number": "16", "ReferenceId": "22729224", "FullCitation": "Rivi\u00e8re JB, et al. Nat. Genet. (2012) pmid: 22729224", "Include": "true"}, {"number": "17", "ReferenceId": "19394761", "FullCitation": "Shibata T, et al. Cancer Lett. (2009) pmid: 19394761", "Include": "true"}, {"number": "18", "ReferenceId": "26627007", "FullCitation": "Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007", "Include": "true"}, {"number": "19", "ReferenceId": "29284706", "FullCitation": "Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706", "Include": "true"}, {"number": "20", "ReferenceId": "29533785", "FullCitation": "Ng PK, et al. Cancer Cell (2018) pmid: 29533785", "Include": "true"}, {"number": "21", "ReferenceId": "32929011", "FullCitation": "Spangle JM, et al. (2020) pmid: 32929011", "Include": "true"}, {"number": "22", "ReferenceId": "29636477", "FullCitation": "Chen L, et al. Nat Commun (2018) pmid: 29636477", "Include": "true"}, {"number": "23", "ReferenceId": "18181165", "FullCitation": "Riener MO, et al. Genes Chromosomes Cancer (2008) pmid: 18181165", "Include": "true"}, {"number": "24", "ReferenceId": "21303542", "FullCitation": "Deshpande V, et al. BMC Cancer (2011) pmid: 21303542", "Include": "true"}, {"number": "25", "ReferenceId": "22180306", "FullCitation": "Borger DR, et al. Oncologist (2012) pmid: 22180306", "Include": "true"}, {"number": "26", "ReferenceId": "24186137", "FullCitation": "Jang S, et al. Mod. Pathol. (2014) pmid: 24186137", "Include": "true"}, {"number": "27", "ReferenceId": "23391413", "FullCitation": "Voss JS, et al. Hum. Pathol. (2013) pmid: 23391413", "Include": "true"}, {"number": "28", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "29", "ReferenceId": "21051183", "FullCitation": "Xu RF, et al. Biomed. Pharmacother. (2011) pmid: 21051183", "Include": "true"}, {"number": "30", "ReferenceId": "18343945", "FullCitation": "Sch\u00f6nleben F, et al. Langenbecks Arch Surg (2008) pmid: 18343945", "Include": "true"}, {"number": "31", "ReferenceId": "21945955", "FullCitation": "Yamaguchi H, et al. Am. J. Surg. Pathol. (2011) pmid: 21945955", "Include": "true"}, {"number": "32", "ReferenceId": "16778113", "FullCitation": "Sch\u00f6nleben F, et al. Clin. Cancer Res. (2006) pmid: 16778113", "Include": "true"}, {"number": "33", "ReferenceId": "21547907", "FullCitation": "Xiao HD, et al. J. Pathol. (2011) pmid: 21547907", "Include": "true"}, {"number": "34", "ReferenceId": "20495538", "FullCitation": "Kuboki Y, et al. Mod. Pathol. (2010) pmid: 20495538", "Include": "true"}, {"number": "35", "ReferenceId": "19440799", "FullCitation": "Sch\u00f6nleben F, et al. J. Gastrointest. Surg. (2009) pmid: 19440799", "Include": "true"}, {"number": "36", "ReferenceId": "24608574", "FullCitation": "Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574", "Include": "true"}, {"number": "37", "ReferenceId": "29401002", "FullCitation": "Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002", "Include": "true"}, {"number": "38", "ReferenceId": "30793038", "FullCitation": "Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038", "Include": "true"}, {"number": "39", "ReferenceId": "31091374", "FullCitation": "Andr\u00e9 F, et al. N. Engl. J. Med. (2019) pmid: 31091374", "Include": "true"}, {"number": "40", "ReferenceId": "33863913", "FullCitation": "Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913", "Include": "true"}, {"number": "41", "ReferenceId": "27105424", "FullCitation": "Park HS, et al. PLoS ONE (2016) pmid: 27105424", "Include": "true"}, {"number": "42", "ReferenceId": "26859683", "FullCitation": "Lim SM, et al. Oncotarget (2016) pmid: 26859683", "Include": "true"}, {"number": "43", "ReferenceId": "25426553", "FullCitation": "Hou MM, et al. Oncotarget (2014) pmid: 25426553", "Include": "true"}, {"number": "44", "ReferenceId": "31351267", "FullCitation": "Varnier R, et al. Eur J Cancer (2019) pmid: 31351267", "Include": "true"}, {"number": "45", "ReferenceId": "24440717", "FullCitation": "Janku F, et al. Cell Rep (2014) pmid: 24440717", "Include": "true"}, {"number": "46", "ReferenceId": "22927482", "FullCitation": "Moroney J, et al. Clin. Cancer Res. (2012) pmid: 22927482", "Include": "true"}, {"number": "47", "ReferenceId": "27893038", "FullCitation": "Basho RK, et al. JAMA Oncol (2017) pmid: 27893038", "Include": "true"}, {"number": "48", "ReferenceId": "21890452", "FullCitation": "Moroney JW, et al. Clin. Cancer Res. (2011) pmid: 21890452", "Include": "true"}, {"number": "49", "ReferenceId": "32958578", "FullCitation": "Pascual J, et al. Cancer Discov (2021) pmid: 32958578", "Include": "true"}, {"number": "50", "ReferenceId": "26787751", "FullCitation": "Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751", "Include": "true"}, {"number": "51", "ReferenceId": "2941002", "FullCitation": "Aust Fam Physician (1986) pmid: 2941002", "Include": "true"}, {"number": "52", "ReferenceId": "31934607", "FullCitation": "Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607", "Include": "true"}, {"number": "53", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "54", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "55", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "56", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "57", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "58", "ReferenceId": "19866438", "FullCitation": "Mishra PK, et al. Genet. Mol. Res. (2009) pmid: 19866438", "Include": "true"}, {"number": "59", "ReferenceId": "18176964", "FullCitation": "Nagahashi M, et al. World J. Gastroenterol. (2008) pmid: 18176964", "Include": "true"}, {"number": "60", "ReferenceId": "15963980", "FullCitation": "Saetta AA, et al. Exp. Mol. Pathol. (2006) pmid: 15963980", "Include": "true"}, {"number": "61", "ReferenceId": "15692793", "FullCitation": "Roa JC, et al. J. Gastroenterol. (2005) pmid: 15692793", "Include": "true"}, {"number": "62", "ReferenceId": "12766614", "FullCitation": "Sessa F, et al. Diagn. Mol. Pathol. (2003) pmid: 12766614", "Include": "true"}, {"number": "63", "ReferenceId": "12374683", "FullCitation": "Rashid A, et al. Clin. Cancer Res. (2002) pmid: 12374683", "Include": "true"}, {"number": "64", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "65", "ReferenceId": "12175538", "FullCitation": "Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538", "Include": "true"}, {"number": "66", "ReferenceId": "12402306", "FullCitation": "Liu D, et al. Int. J. Cancer (2002) pmid: 12402306", "Include": "true"}, {"number": "67", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "68", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "69", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "70", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "71", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "72", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "73", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "74", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "75", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "76", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "77", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "78", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "79", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "80", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "81", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "82", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "83", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "84", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "85", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "86", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "87", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "88", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "89", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "90", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "91", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "92", "ReferenceId": "22200773", "FullCitation": "Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773", "Include": "true"}, {"number": "93", "ReferenceId": "21507354", "FullCitation": "Prog Mol Biol Transl Sci (2011) pmid: 21507354", "Include": "true"}, {"number": "94", "ReferenceId": "21887466", "FullCitation": "Yang J, et al. Mol Med Rep () pmid: 21887466", "Include": "true"}, {"number": "95", "ReferenceId": "16870044", "FullCitation": "Vallb\u00f6hmer D, et al. Clin Lung Cancer (2006) pmid: 16870044", "Include": "true"}, {"number": "96", "ReferenceId": "21351083", "FullCitation": "Daskalos A, et al. Cancer (2011) pmid: 21351083", "Include": "true"}, {"number": "97", "ReferenceId": "17890317", "FullCitation": "Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317", "Include": "true"}, {"number": "98", "ReferenceId": "22011581", "FullCitation": "Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581", "Include": "true"}, {"number": "99", "ReferenceId": "23031157", "FullCitation": "Kim MS, et al. APMIS (2013) pmid: 23031157", "Include": "true"}, {"number": "100", "ReferenceId": "15861382", "FullCitation": "Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382", "Include": "true"}, {"number": "101", "ReferenceId": "25383530", "FullCitation": "Guo X, et al. Nature (2015) pmid: 25383530", "Include": "true"}, {"number": "102", "ReferenceId": "30705090", "FullCitation": "Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090", "Include": "true"}, {"number": "103", "ReferenceId": "29414941", "FullCitation": "Zhang ZM, et al. Nature (2018) pmid: 29414941", "Include": "true"}, {"number": "104", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "105", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "106", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "107", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "108", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "109", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "110", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "111", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "112", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "113", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "114", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "115", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "116", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "117", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "118", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "119", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "120", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "121", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "122", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "123", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "124", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "125", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "126", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "127", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "128", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "129", "ReferenceId": "26258846", "FullCitation": "Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846", "Include": "true"}, {"number": "130", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "131", "ReferenceId": "22722792", "FullCitation": "Reungwetwattana T, et al. J Thorac Oncol (2012) pmid: 22722792", "Include": "true"}, {"number": "132", "ReferenceId": "23514584", "FullCitation": "Spindler KL, et al. Acta Oncol (2013) pmid: 23514584", "Include": "true"}, {"number": "133", "ReferenceId": "20630061", "FullCitation": "Javle MM, et al. BMC Cancer (2010) pmid: 20630061", "Include": "true"}, {"number": "134", "ReferenceId": "25878190", "FullCitation": "Moulder S, et al. Ann. Oncol. (2015) pmid: 25878190", "Include": "true"}, {"number": "135", "ReferenceId": "23066039", "FullCitation": "Janku F, et al. Cancer Res. (2013) pmid: 23066039", "Include": "true"}, {"number": "136", "ReferenceId": "22271473", "FullCitation": "Janku F, et al. J. Clin. Oncol. (2012) pmid: 22271473", "Include": "true"}, {"number": "137", "ReferenceId": "21216929", "FullCitation": "Janku F, et al. Mol. Cancer Ther. (2011) pmid: 21216929", "Include": "true"}, {"number": "138", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "139", "ReferenceId": "24827133", "FullCitation": "Buzzoni R, et al. Ann. Oncol. (2014) pmid: 24827133", "Include": "true"}, {"number": "140", "ReferenceId": "25145431", "FullCitation": "Verzoni E, et al. Future Oncol (2014) pmid: 25145431", "Include": "true"}, {"number": "141", "ReferenceId": "24740268", "FullCitation": "Costello BA, et al. Invest New Drugs (2014) pmid: 24740268", "Include": "true"}, {"number": "142", "ReferenceId": "29527009", "FullCitation": "Lau DK, et al. Br J Cancer (2018) pmid: 29527009", "Include": "true"}, {"number": "143", "ReferenceId": "32323774", "FullCitation": "Feng F, et al. Oncol Rep (2020) pmid: 32323774", "Include": "true"}, {"number": "144", "ReferenceId": "28694672", "FullCitation": "Bian JL, et al. World J Gastroenterol (2017) pmid: 28694672", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_02_04 21:43:01", "OpName": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "0%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BILE DUCT", "disease_ontology": "Bile duct adenocarcinoma", "flowcell_analysis": "2000019927", "gender": "female", "pathology_diagnosis": "gallbladder cancer", "pipeline_version": "v3.10.0", "purity_assessment": "13.0", "specimen": "ORD_1289646_01*US1240879.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1289646_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1240879.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.5164", "cds_effect": "3401A>G", "depth": "1743", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "51.64", "position": "chr9:139402516", "protein_effect": "Q1134R", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.0093", "cds_effect": "2036A>G", "depth": "970", "equivocal": "false", "functional_effect": "missense", "gene": "WHSC1L1", "percent_reads": "0.93", "position": "chr8:38173013", "protein_effect": "D679G", "status": "unknown", "strand": "_", "transcript": "NM_023034", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.0087", "cds_effect": "660C>A", "depth": "807", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH2", "percent_reads": "0.87", "position": "chr1:120539711", "protein_effect": "S220R", "status": "unknown", "strand": "_", "transcript": "NM_024408", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.0017", "cds_effect": "1633G>A", "depth": "4206", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "0.17", "position": "chr3:178936091", "protein_effect": "E545K", "status": "known", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.4874", "cds_effect": "649C>T", "depth": "1108", "equivocal": "false", "functional_effect": "missense", "gene": "MLH1", "percent_reads": "48.74", "position": "chr3:37053562", "protein_effect": "R217C", "status": "unknown", "strand": "+", "transcript": "NM_000249", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.0057", "cds_effect": "717_729delGGAGGAGGCCAGC", "depth": "2293", "equivocal": "false", "functional_effect": "frameshift", "gene": "DNMT3A", "percent_reads": "0.57", "position": "chr2:25471031", "protein_effect": "E240fs*72", "status": "likely", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.4965", "cds_effect": "487G>T", "depth": "1875", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "49.65", "position": "chr2:30143039", "protein_effect": "V163L", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.4845", "cds_effect": "2599G>A", "depth": "1618", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "48.45", "position": "chr2:29455203", "protein_effect": "V867I", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.5034", "cds_effect": "115G>A", "depth": "445", "equivocal": "false", "functional_effect": "missense", "gene": "XRCC2", "percent_reads": "50.34", "position": "chr7:152357792", "protein_effect": "V39M", "status": "unknown", "strand": "_", "transcript": "NM_005431", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.4524", "cds_effect": "622G>A", "depth": "1282", "equivocal": "false", "functional_effect": "missense", "gene": "DDR1", "percent_reads": "45.24", "position": "chr6:30859213", "protein_effect": "V208M", "status": "unknown", "strand": "+", "transcript": "NM_001954", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}, {"allele_fraction": "0.5338", "cds_effect": "12761A>G", "depth": "2396", "equivocal": "false", "functional_effect": "missense", "gene": "MLL2", "percent_reads": "53.38", "position": "chr12:49425727", "protein_effect": "Q4254R", "status": "unknown", "strand": "_", "transcript": "NM_003482", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": {"organism": "HHV_4", "reads_per_million": "31", "status": "unknown", "dna_evidence": {"sample": "SQ_US1240879.01_1"}}}}}}}